Last updated: February 2026
Clinical trials are the pathway to better treatments. For low-grade serous ovarian cancer, where treatment options are still being refined and standardized care approaches continue to evolve, participating in research studies can provide access to innovative approaches and contribute to advancing care for future patients.
Clinical Trials for LGSOC
💊 Treatment Studies
These studies test new therapies or combinations of treatments:
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
- Location: 19 hospitals across Italy
- What it is: Comparing letrozole (hormone therapy) to standard chemotherapy as first-line treatment
- Who can participate: Women with newly diagnosed, advanced LGSOC that is hormone receptor positive
- Duration: Through 2029
- Sponsor: Ente Ospedaliero Ospedali Galliera
- Why it matters: Could offer a less toxic alternative to chemotherapy for hormone-positive LGSOC
- Study ID: NCT05601700
Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)
- Location: 100+ locations across United States, Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Korea, Netherlands, New Zealand, Poland, Spain, and United Kingdom
- What it is: Testing combination of avutometinib and defactinib versus standard care for recurrent LGSOC
- Who can participate: Women with recurrent LGSOC who have progressed on prior platinum-based therapy
- Duration: Through 2031
- Sponsor: Verastem, Inc.
- Why it matters: First Phase 3 trial specifically for LGSOC with breakthrough therapy designation
- Study ID: NCT06072781
Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer (CHAMELEON)
- Location: Memorial Sloan Kettering Cancer Center and satellite locations (New York, New Jersey, Georgia)
- What it is: Testing triple combination therapy in the upfront setting for newly diagnosed LGSOC
- Who can participate: Women with LGSOC not suitable for primary surgery or with residual disease after surgery
- Duration: Through 2027
- Sponsor: Memorial Sloan Kettering Cancer Center
- Why it matters: Novel approach combining targeted therapy with hormone therapy for initial treatment
- Study ID: NCT06394804
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
- Location: University of Oklahoma (Oklahoma City)
- What it is: Testing nab-sirolimus plus fulvestrant combination
- Who can participate: Women with recurrent LGSOC with measurable disease
- Duration: Through 2029
- Sponsor: University of Oklahoma
- Why it matters: Explores mTOR pathway inhibition combined with hormone therapy
- Study ID: NCT06494150
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
- Location: Case Comprehensive Cancer Center (Cleveland, Ohio)
- What it is: Testing regorafenib (multi-kinase inhibitor) plus fulvestrant hormone therapy
- Who can participate: Women with recurrent LGSOC, up to 5 prior lines of therapy allowed
- Duration: Through 2025
- Sponsor: Sarah K. Lynam MD
- Why it matters: Novel combination targeting multiple pathways in LGSOC
- Study ID: NCT05113368
🔬 Registry Studies
These studies collect data to better understand LGSOC patterns and outcomes:
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
- Location: MD Anderson Cancer Center (Houston, Texas)
- What it is: Long-term data collection on LGSOC patients and tissue banking
- Who can participate: Women with low-grade ovarian or peritoneal tumors
- Duration: Ongoing through 2035 (started 2006)
- Sponsor: M.D. Anderson Cancer Center
- Why it matters: Creates comprehensive database to understand LGSOC behavior and outcomes
- Study ID: NCT00488878
🧬 Multi-Disease Studies Including LGSOC
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib
- Location: Dana-Farber Cancer Institute and affiliates (Massachusetts)
- What it is: Testing CDK4/6 inhibitor plus hormone therapy combinations (includes LGSOC cohort)
- Who can participate: Women with LGSOC (Cohort 5), regardless of hormone receptor status
- Duration: Through 2031
- Sponsor: Dana-Farber Cancer Institute
- Why it matters: Explores CDK4/6 inhibition specifically in LGSOC
- Study ID: NCT03675893
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO)
- Location: 12 hospitals across Belgium, France, and Netherlands
- What it is: Testing CDK4/6 inhibitor plus aromatase inhibitor in hormone-positive rare ovarian cancers
- Who can participate: Women with recurrent ER+ LGSOC or endometrioid ovarian cancer
- Duration: Through 2028
- Sponsor: Universitaire Ziekenhuizen KU Leuven
- Why it matters: Brings proven breast cancer combination to hormone-positive ovarian cancers
- Study ID: NCT05872204
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
- Location: 43 hospitals across Austria, Germany, and Switzerland
- What it is: Testing letrozole maintenance therapy versus placebo after standard treatment
- Who can participate: Women with LGSOC and high-grade ovarian cancers that are estrogen receptor positive
- Duration: Through 2030
- Sponsor: Swiss GO Trial Group
- Why it matters: Could establish hormone therapy as standard maintenance for ER+ ovarian cancers
- Study ID: NCT04111978
Testing Different Amounts of M1774 and ZEN-3694 for Recurrent Ovarian and Endometrial Cancer
- Location: 14 locations across United States
- What it is: Phase 1b dose-finding study of ATR inhibitor plus BET inhibitor combination
- Who can participate: Women with recurrent LGSOC among other tumor types
- Duration: Through 2026
- Sponsor: National Cancer Institute (NCI)
- Why it matters: Novel approach targeting DNA repair and epigenetic pathways
- Study ID: NCT05950464
Study of Ubamatamab (REGN4018) Alone or in Combination With Cemiplimab in Recurrent Ovarian Cancer or Other MUC16+ Cancers
- Location: 51+ locations across the United States, Belgium, France, Israel, Italy, Netherlands, South Korea, Spain, and United Kingdom
- What it is: Phase 1/2 study testing ubamatamab, a MUC16×CD3 bispecific antibody, alone or combined with the immunotherapy cemiplimab, in recurrent ovarian and endometrial cancers
- Who can participate: Women with recurrent advanced epithelial ovarian cancer (including a dedicated LGSOC cohort), fallopian tube cancer, primary peritoneal cancer, or endometrial cancer; must have received at least one prior platinum-based therapy
- Duration: Through January 2027
- Sponsor: Regeneron Pharmaceuticals
- Why it matters: Tests a novel immunotherapy approach targeting MUC16, a protein commonly expressed in ovarian cancer, with a specific cohort for LGSOC patients
- Study ID: NCT03564340
How to Find Clinical Trials
🔍 Search Resources
- ClinicalTrials.gov: Official U.S. database of clinical studies
- Cancer.gov Clinical Trials Search: NCI’s patient-friendly search tool
- Your gynecologic oncologist: Often has access to institutional trials
📋 Questions to Ask Your Doctor
When discussing clinical trials, consider asking:
- What are the potential benefits and risks?
- How does this compare to standard treatment?
- What follow-up care is required?
- Will my insurance cover trial-related costs?
Understanding Trial Phases
- Observational Studies: Like registries, these collect information without testing treatments
- Phase I: Test safety of new treatments in small groups
- Phase II: Evaluate effectiveness while monitoring safety
- Phase III: Compare new treatments to current standard care
What to Expect
Before Joining
- Detailed informed consent process
- Review of your medical history
- Physical exams and tests
- Discussion of time commitment
During Participation
- Regular study visits
- Careful monitoring of your health
- Access to study team for questions
- Detailed record-keeping
Financial Considerations
Many clinical trials cover:
- Study-related medical care
- Research tests and procedures
- Study medications (if applicable)
You’re typically responsible for:
- Travel costs (some studies provide assistance)
- Regular medical care unrelated to the study
- Personal expenses
Special Considerations for Younger Women
Since low-grade serous ovarian cancer often affects younger women, many trials consider:
- Fertility preservation options
- Long-term quality of life impacts
- Work and family considerations
Stay Updated: Low-Grade Serous Ovarian Cancer Clinical Trials
New trials open regularly. Bookmark this page and check back for updates, or sign up for our newsletter to stay informed about research developments.